Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Neurobiology
SJR: 0.121

ISSN Print: 0892-0915
ISSN Online: 2375-0014

Archives: Volume 10, 1996 to Volume 20, 2008

Critical Reviews™ in Neurobiology

DOI: 10.1615/CritRevNeurobiol.v16.i12.90
pages 83-90

Neuroprotective and Neurotrophic Actions of the Mood Stabilizer Lithium: Can It Be Used to Treat Neurodegenerative Diseases?

De-Maw Chuang
Molecular Neurobiology Section, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA


The mood stabilizing drug lithium has emerged as a robust neuroprotective agent in preventing apoptosis of neurons. Long-term treatment with lithium effectively protects primary cultures of rat brain neurons from glutamate-induced, NMDA receptor-mediated excitotoxicity. This neuroprotection is accompanied by an inhibition of NMDA-receptor—mediated calcium influx, upregulation of anti-apoptotic Bcl-2, downregulation of pro-apoptotic p53 and Bax, and activation of cell survival factors. Lithium treatment antagonizes glutamate-induced activation of c-Jun-N-terminal kinase (JNK), p38 kinase, and AP-1 binding, which has a major role in cytotoxicity, and suppresses glutamate-induced loss of phosphorylated cAMP responsive element binding protein (CREB). Lithium also induces the expression of brain-derived neurotrophic factor (BDNF) and subsequent activation TrkB, the receptor for BDNF, in cortical neurons. The activation of BDNF/TrkB signaling is essential for the neuroprotective effects of this drug. In addition, lithium stimulates the proliferation of neuroblasts in primary cultures of CNS neurons.
Lithium also shows neuroprotective effects in rodent models of diseases. In a rat model of stroke, post-insult treatment with lithium or valproate, another mood stabilizer, at therapeutic doses markedly reduces brain infarction and neurological deficits. This neuroprotection is associated with suppression of caspase-3 activation and induction of chaperone proteins such as heat shock protein 70. In a rat model of Huntington's disease (HD) in which an excitotoxin is unilaterally infused into the striatum, both long- and short-term pretreatment with lithium reduces DNA damage, caspase-3 activation, and loss of striatal neurons. This neuroprotection is associated with upregulation of Bcl-2. Lithium also induces cell proliferation near the injury site with a concomitant loss of proliferating cells in the subventricular zone. Some of these proliferating cells display neuronal or astroglial phenotypes. These results corroborate our findings obtained in primary neuronal cultures. The neuroprotective and neurotrophic actions of lithium have profound clinical implications. In addition to its present use in bipolar patients, lithium could be used to treat acute brain injuries such as stroke and chronic progressive neurodegenerative diseases.

Articles with similar content:

Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Muhammad Zaeem Noman, Markus Ollert, Ludovic Menard, Malina Xiao, Bassam Janji, Martyna Szpakowska, Andy Chevigne, Guy Berchem, Manon Bosseler
The Adenoma-Carcinoma Sequence and Prospects for the Prevention of Colorectal Neoplasia
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Julian Little, Seonaidh Cotton, Linda Sharp
Neurosteroids and Ischemic Stroke: Progesterone a Promising Agent in Reducing the Brain Injury in Ischemic Stroke
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 3
Syed Suhail Andrabi, Suhel Parvez, Heena Tabassum
Inositol Hexaphosphate Induces Apoptosis by Coordinative Modulation of P53, Bcl-2 and Sequential Activation of Caspases in 7,12 Dimeth-ylbenz [a] anthracene Exposed Mouse Epidermis
Journal of Environmental Pathology, Toxicology and Oncology, Vol.27, 2008, issue 3
Jaya Singh, Krishna P. Gupta
Nitric Oxide-Mediated Regulation of Cancer Immune Escape
Onco Therapeutics, Vol.1, 2010, issue 4
D. Robert Siemens, Charles H. Graham